The Safety and Efficacy of Infliximab in Moderate to Severe Chronic Obstructive Pulmonary Disease

2007431 citationsJournal Article

Authors

Stephen I. Rennard · University of Nebraska Medical Center

Charles Fogarty · Spartanburg Community College

Steven G. Kelsen · University Medical Center

W.A. Long · University of North Carolina at Charlotte

Joe Ramsdell · University of California San Diego

James E. Allison · Columbia College - South Carolina

Donald A. Mahler

Abstract

Subjects with moderate to severe COPD did not benefit from treatment with infliximab. Although not statistically significant, more cases of cancer and pneumonia were observed in the infliximab-treated subjects. The impact of infliximab on malignancy risk in patients with COPD needs to be further elucidated.

Topics & Keywords

Chronic Obstructive Pulmonary Disease (COPD) Research Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Asthma and respiratory diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: American Journal of Respiratory and Critical Care Medicine

Volume 175, Issue 9, pp. 926-934

DOI: 10.1164/rccm.200607-995oc

Field-Weighted Citation Impact: 34.44